MAACU / Montes Archimedes Acquisition Corp - Units (1 Ord Share Class A & 1/2 War) - Depositi SEC, Relazione annuale, dichiarazione di delega

Montes Archimedes Acquisition Corp., Class A / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 2) MONTES ARCHIMEDES ACQUISITION CORP. (Name of Issuer) CLASS A COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 612657106 (CUSIP Number) DECEMBER 31, 2021 (Date of event which requires filing of this statement) Check the appropriate

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-39597 Montes Archimedes Acquisition Corp. (Exact name of registrant as s

US6126571065 / Montes Archimedes Acquisition Corp., Class A / Patient Square Capital LLC - SCHEDULE 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Montes Archimedes Acquisition Corp. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 612657106 (CUSIP Number) September 30, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropri

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 30, 2021 MONTES ARCHIMEDES ACQUISITION CORP. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-39597 (Commis

Amendment No. 2 to the Sponsor Support Agreement, dated as of September 30, 2021, among Roivant, MAAC, MAAC Sponsor and the other parties thereto

Exhibit 10.1 AMENDMENT NO. 2 to Sponsor support agreement This Amendment No. 2 to the Sponsor Support Agreement (this ?Amendment?) is made as of September 30, 2021, by and among Roivant Sciences Ltd., a Bermuda exempted limited company (the ?Company?), Montes Archimedes Acquisition Corp., a Delaware corporation (?MAAC?), Patient Square Capital LLC, a Delaware limited liability company (the ?MAAC S

Other Events, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 28, 2021 MONTES ARCHIMEDES ACQUISITION CORP. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-39597 (Commis

Montes Archimedes Acquisition Corp., Class A / Beryl Capital Management LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Montes Archimedes Acquisition Corp. (Name of Issuer) Class A Common Stock, par value $0.0001 (Title of Class of Securities) 612657106 (CUSIP Number) September 17, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to de

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 21, 2021 MONTES ARCHIMEDES ACQUISITION CORP. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-39597 (Commis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 21, 2021 MONTES ARCHIME

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 21, 2021 MONTES ARCHIMEDES ACQUISITION CORP. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-39597 (Commis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ◻ TRANSITION REPORT PURSUANT TO S

Table of Contents ? ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2021 MONTES ARCHIMEDES ACQUISITION CORP. (Exact name of registrant as specified in its charter) Delaware 001-39597 85-1830874 (State or other jurisdiction of incorpo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2021 MONTES ARC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2021 MONTES ARCHIMEDES ACQUISITION CORP. (Exact name of registrant as specified in its charter) Delaware 001-39597 85-1830874 (State or other jurisdiction of incorpo

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2021 MONTES ARCHIMEDES ACQUISITION CORP. (Exact name of registrant as specified in its charter) Delaware 001-39597 85-1830874 (State or other jurisdiction of incorpor

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2021 MONTES ARCH

425 1 tm2121791d38k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2021 MONTES ARCHIMEDES ACQUISITION CORP. (Exact name of registrant as specified in its charter) Delaware 001-39597 85-1830874 (State

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2021 MONTES ARCHIMEDES ACQUISITION CORP. (Exact name of registrant as specified in its charter) Delaware 001-39597 85-1830874 (State or other jurisdiction of incorpora

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2021 MONTES ARCHI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2021 MONTES ARCHIMEDES ACQUISITION CORP. (Exact name of registrant as specified in its charter) Delaware 001-39597 85-1830874 (State or other jurisdiction of incorpora

Roivant Overview June 2021 Statement of Limitations (1/2) This investor presentation (this “Presentation”) was prepared by Montes Archimedes Acquisition Corp. (“SPAC”) and Roivant Sciences Ltd. (the “Company”) in connection with the proposed transact

Exhibit 99.1 Roivant Overview June 2021 Statement of Limitations (1/2) This investor presentation (this ?Presentation?) was prepared by Montes Archimedes Acquisition Corp. (?SPAC?) and Roivant Sciences Ltd. (the ?Company?) in connection with the proposed transactions (the ?Business Combination?) contemplated by the Business Combination Agreement, by and among SPAC, the Company and one of its affil

Roivant Overview June 2021 Statement of Limitations (1/2) This investor presentation (this “Presentation”) was prepared by Montes Archimedes Acquisition Corp. (“SPAC”) and Roivant Sciences Ltd. (the “Company”) in connection with the proposed transact

Exhibit 99.1 Roivant Overview June 2021 Statement of Limitations (1/2) This investor presentation (this ?Presentation?) was prepared by Montes Archimedes Acquisition Corp. (?SPAC?) and Roivant Sciences Ltd. (the ?Company?) in connection with the proposed transactions (the ?Business Combination?) contemplated by the Business Combination Agreement, by and among SPAC, the Company and one of its affil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2021 MONTES ARCH

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2021 MONTES ARCHIMEDES ACQUISITION CORP. (Exact name of registrant as specified in its charter) Delaware 001-39597 85-1830874 (State or other jurisdiction of incorpor

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2021 MONTES ARCHIMEDES ACQUISITION CORP. (Exact name of registrant as specified in its charter) Delaware 001-39597 85-1830874 (State or other jurisdiction of incorpor

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2021 MONTES ARCHIMEDES ACQUISITION CORP. (Exact name of registrant as specified in its charter) Delaware 001-39597 85-1830874 (State or other jurisdiction of incorpor

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2021 MONTES ARCH

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2021 MONTES ARCHIMEDES ACQUISITION CORP. (Exact name of registrant as specified in its charter) Delaware 001-39597 85-1830874 (State or other jurisdiction of incorpor

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2021 MONTES ARCHI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2021 MONTES ARCHIMEDES ACQUISITION CORP. (Exact name of registrant as specified in its charter) Delaware 001-39597 85-1830874 (State or other jurisdiction of incorpora

Amendment No. 1 to the Business Combination Agreement, dated as of June 9, 2021, by and among Montes Archimedes Acquisition Corp, Roivant Sciences Ltd. and Rhine Merger Sub, Inc.

Exhibit 2.1 AMENDMENT NO. 1 to Business Combination Agreement This Amendment No. 1 to the Business Combination Agreement (this ?Amendment?) is made as of June 9, 2021, by and among Montes Archimedes Acquisition Corp., a Delaware corporation (?MAAC?), and Roivant Sciences Ltd., a Bermuda exempted limited company (the ?Company?). Capitalized terms used, but not otherwise defined herein, shall have t

Form of Lock-Up Agreement, dated as of June 9, 2021, by and among Roivant Sciences Ltd. and certain other persons party thereto.

Exhibit 10.2 FORM OF LOCK-UP AGREEMENT This LOCK-UP AGREEMENT (this ?Agreement?) is entered into as of June 9, 2021, by and among Roivant Sciences Ltd., a Bermuda exempted limited company (the ?Company?), and the undersigned person (the ?Holder?). Each of the Company and the Holder are sometimes referred to herein individually as a ?Party? and collectively as the ?Parties.? Capitalized terms used

Amendment No. 1 to the Sponsor Support Agreement, dated as of June 9, 2021, by and among Patient Square Capital LLC, Montes Archimedes Acquisition Corp, Roivant Sciences Ltd. and certain other persons party thereto.

Exhibit 10.1 AMENDMENT NO. 1 to Sponsor support agreement This Amendment No. 1 to the Sponsor Support Agreement (this ?Amendment?) is made as of June 9, 2021, by and among Roivant Sciences Ltd., a Bermuda exempted limited company (the ?Company?), Montes Archimedes Acquisition Corp., a Delaware corporation (?MAAC?), Patient Square Capital LLC, a Delaware limited liability company (the ?MAAC Sponsor

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2021 MONTES ARCHI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2021 MONTES ARCHIMEDES ACQUISITION CORP. (Exact name of registrant as specified in its charter) Delaware 001-39597 85-1830874 (State or other jurisdiction of incorpora

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2021 MONTES ARCHIMEDES ACQUISITION CORP. (Exact name of registrant as specified in its charter) Delaware 001-39597 85-1830874 (State or other jurisdiction of incorpora

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2021 MONTES ARCHIMEDES ACQUISITION CORP. (Exact name of registrant as specified in its charter) Delaware 001-39597 85-1830874 (State or other jurisdiction of incorpora

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 ¨ TRANSITION REPORT PURSUANT TO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto MONTES ARCHIMEDES ACQUISITION CORP. (Exact name of regi

JOINT FILING AGREEMENT

EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the Class A common stock of Montes Archimedes Acquisition Corp., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, as amended, on beh

May 6, 2021

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G*/ (Rule 13d-102) Montes Archimedes Acquisition Corp. (Name of Issuer) Class A common stock, par value $0.0001 per share (Title of Class of Securities) 612657106 (CUSIP Number) May 6, 2021 Date of Event Which Requires Filing of the Statement Check the appropriate box to designate the rule pursuant to which this Sch

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2021 MONTES ARCHIMEDES ACQUISITION CORP. (Exact name of registrant as specified in its charter) Delaware 001-39597 85-1830874 (State or other jurisdiction of incorpora

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING

NT 10-Q 1 tm2116623d1nt10q.htm NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING 001-39597 SEC FILE NUMBER 612657 106 CUSIP NUMBER (Check One): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q and Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: March 31, 2021 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2021 MONTES ARCHI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2021 MONTES ARCHIMEDES ACQUISITION CORP. (Exact name of registrant as specified in its charter) Delaware 001-39597 85-1830874 (State or other jurisdiction of incorpora

Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2021 MONTES ARCHIMEDES ACQUISITION CORP. (Exact name of registrant as specified in its charter) Delaware 001-39597 85-1830874 (State or other jurisdiction of incorpora

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A (Amendment No.1)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A (Amendment No.1) (Mark One) x Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2020. ? Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to . Commission File Number: 001-3

Investor Presentation, dated May 2021

Exhibit 99.2 Roivant Overview May 2021 This confidential investor presentation (this ?Presentation?) was prepared by Montes Archimedes Acquisition Corp. (?SPAC?) an d Roivant Sciences Ltd. (the ?Company?). This Presentation is for its intended audience and for informational purposes only, and is not intended for reproduction or a ny further dissemination beyond its initial intended recipients with

Roivant Sciences and Montes Archimedes Acquisition Corp. (MAAC) to Combine and Create Publicly Traded Leader in Biopharma and Health Technology

Exhibit 99.1 Roivant Sciences and Montes Archimedes Acquisition Corp. (MAAC) to Combine and Create Publicly Traded Leader in Biopharma and Health Technology ? Transaction includes $411 million in trust at MAAC and a concurrent, fully committed $200 million PIPE financing from leading healthcare investors including Fidelity Management & Research Company LLC, Eventide Asset Management, Suvretta Capi

[Important Information is Included on the Next Page]

Exhibit 99.3 Vivek Ramaswamy I?m Vivek Ramaswamy. I'm the founder and executive chairman of Roivant. Prior to founding Roivant, I was an investor in the biotech industry for seven years, where I focused on pre-commercial companies. Prior to that, my background was in molecular biology as an undergrad. I also have a background in law along the way, and I left my career as an investor in 2014 to fou

Form of Subscription Agreement

Exhibit 10.2 FINAL FORM SUBSCRIPTION AGREEMENT Montes Archimedes Acquisition Corp. 724 Oak Grove, Suite 130 Menlo Park, CA 94025 Ladies and Gentlemen: This Subscription Agreement (this ?Subscription Agreement?) is being entered into as of the date set forth on the signature page hereto, by and among Montes Archimedes Acquisition Corp., a Delaware corporation (?SPAC?), the undersigned subscriber (t

Sponsor Support Agreement, dated as of May 1, 2021, by and among Patient Square Capital LLC, Montes Archimedes Acquisition Corp, Roivant Sciences Ltd. and certain other persons party thereto

Exhibit 10.1 EXECUTION VERSION SPONSOR SUPPORT AGREEMENT This SPONSOR SUPPORT AGREEMENT (this ?Agreement?) is entered into as of May 1, 2021, by and among Roivant Sciences Ltd., a Bermuda exempted limited company (the ?Company?), Montes Archimedes Acquisition Corp., a Delaware corporation (?MAAC?), Patient Square Capital LLC, a Delaware limited liability company (the ?MAAC Sponsor?), and solely fo

Investor Presentation, dated May 2021

Exhibit 99.2 Roivant Overview May 2021 This confidential investor presentation (this ?Presentation?) was prepared by Montes Archimedes Acquisition Corp. (?SPAC?) an d Roivant Sciences Ltd. (the ?Company?). This Presentation is for its intended audience and for informational purposes only, and is not intended for reproduction or a ny further dissemination beyond its initial intended recipients with

Sponsor Support Agreement, dated as of May 1, 2021, by and among Patient Square Capital LLC, Montes Archimedes Acquisition Corp, Roivant Sciences Ltd. and certain other persons party thereto

Exhibit 10.1 EXECUTION VERSION SPONSOR SUPPORT AGREEMENT This SPONSOR SUPPORT AGREEMENT (this ?Agreement?) is entered into as of May 1, 2021, by and among Roivant Sciences Ltd., a Bermuda exempted limited company (the ?Company?), Montes Archimedes Acquisition Corp., a Delaware corporation (?MAAC?), Patient Square Capital LLC, a Delaware limited liability company (the ?MAAC Sponsor?), and solely fo

Merger Prospectus - FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 1, 2021 MONTES ARCHIMEDES ACQUISITION CORP.

Business Combination Agreement, dated as of May 1, 2021, by and among Montes Archimedes Acquisition Corp, Roivant Sciences Ltd. and Rhine Merger Sub, Inc.

Exhibit 2.1 Execution Version BUSINESS COMBINATION AGREEMENT BY AND AMONG MONTES ARCHIMEDES ACQUISITION CORP., RHINE MERGER SUB, INC., AND ROIVANT SCIENCES LTD. DATED AS OF MAY 1, 2021 TABLE OF CONTENTS Page Article 1 CERTAIN DEFINITIONS 4 Section 1.1 Definitions 4 Article 2 MERGER 21 Section 2.1 Closing Transactions 21 Section 2.2 Closing of the Transactions Contemplated by this Agreement 22 Sect

Business Combination Agreement, dated as of May 1, 2021, by and among Montes Archimedes Acquisition Corp, Roivant Sciences Ltd. and Rhine Merger Sub, Inc.

Exhibit 2.1 Execution Version BUSINESS COMBINATION AGREEMENT BY AND AMONG MONTES ARCHIMEDES ACQUISITION CORP., RHINE MERGER SUB, INC., AND ROIVANT SCIENCES LTD. DATED AS OF MAY 1, 2021 TABLE OF CONTENTS Page Article 1 CERTAIN DEFINITIONS 4 Section 1.1 Definitions 4 Article 2 MERGER 21 Section 2.1 Closing Transactions 21 Section 2.2 Closing of the Transactions Contemplated by this Agreement 22 Sect

Merger Prospectus - FORM 425

Filed by Roivant Sciences Ltd. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Montes Archimedes Acquisition Corp. Commission File No. 001-39597 Date: May 3, 2021 The following message was posted on Twitter on May 3, 2021 by Roivant Sciences: ?We're excited to begin our life as a public compan

Form of Transaction Support Agreement

Exhibit 10.3 FINAL FORM [FORM OF] TRANSACTION SUPPORT AGREEMENT This TRANSACTION SUPPORT AGREEMENT (this ?Agreement?) is entered into as of May 1, 2021, by and among Montes Archimedes Acquisition Corp., a Delaware corporation (?MAAC?), Roivant Sciences Ltd., a Bermuda exempted limited company (the ?Company?), and [?], a [?] ([collectively,] the ?Shareholder?). Each of MAAC, the Company and the Sha

[Important Information is Included on the Next Page]

Exhibit 99.3 Vivek Ramaswamy I?m Vivek Ramaswamy. I'm the founder and executive chairman of Roivant. Prior to founding Roivant, I was an investor in the biotech industry for seven years, where I focused on pre-commercial companies. Prior to that, my background was in molecular biology as an undergrad. I also have a background in law along the way, and I left my career as an investor in 2014 to fou

Form of Transaction Support Agreement

Exhibit 10.3 FINAL FORM [FORM OF] TRANSACTION SUPPORT AGREEMENT This TRANSACTION SUPPORT AGREEMENT (this ?Agreement?) is entered into as of May 1, 2021, by and among Montes Archimedes Acquisition Corp., a Delaware corporation (?MAAC?), Roivant Sciences Ltd., a Bermuda exempted limited company (the ?Company?), and [?], a [?] ([collectively,] the ?Shareholder?). Each of MAAC, the Company and the Sha

Form of Subscription Agreement (incorporated herein by reference to Exhibit 10.2 of Montes Archimedes Acquisition Corp.’s Current Report on Form 8-K, filed with the SEC on May 1, 2021)

Exhibit 10.2 FINAL FORM SUBSCRIPTION AGREEMENT Montes Archimedes Acquisition Corp. 724 Oak Grove, Suite 130 Menlo Park, CA 94025 Ladies and Gentlemen: This Subscription Agreement (this ?Subscription Agreement?) is being entered into as of the date set forth on the signature page hereto, by and among Montes Archimedes Acquisition Corp., a Delaware corporation (?SPAC?), the undersigned subscriber (t

Form of Lock-Up Agreement

Exhibit 10.4 FINAL FORM [FORM OF] LOCK-UP AGREEMENT This LOCK-UP AGREEMENT (this ?Agreement?) is entered into as of May 1, 2021, by and among Roivant Sciences Ltd., a Bermuda exempted limited company (the ?Company?), and the undersigned person[s] ([collectively,] the ?Holder?). Each of the Company and the Holder are sometimes referred to herein individually as a ?Party? and collectively as the ?Pa

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 1, 2021 MONTES ARCHIMEDES ACQUISITION CORP.

Roivant Sciences and Montes Archimedes Acquisition Corp. (MAAC) to Combine and Create Publicly Traded Leader in Biopharma and Health Technology

Exhibit 99.1 Roivant Sciences and Montes Archimedes Acquisition Corp. (MAAC) to Combine and Create Publicly Traded Leader in Biopharma and Health Technology ? Transaction includes $411 million in trust at MAAC and a concurrent, fully committed $200 million PIPE financing from leading healthcare investors including Fidelity Management & Research Company LLC, Eventide Asset Management, Suvretta Capi

Form of Lock-Up Agreement

Exhibit 10.4 FINAL FORM [FORM OF] LOCK-UP AGREEMENT This LOCK-UP AGREEMENT (this ?Agreement?) is entered into as of May 1, 2021, by and among Roivant Sciences Ltd., a Bermuda exempted limited company (the ?Company?), and the undersigned person[s] ([collectively,] the ?Holder?). Each of the Company and the Holder are sometimes referred to herein individually as a ?Party? and collectively as the ?Pa

Description of Registrant’s Securities.*

EXHIBIT 4.5 MONTES ARCHIMEDES ACQUISITION CORP. DESCRIPTION OF SECURITIES The following summary of the material terms of the securities of Montes Archimedes Acquisition Corp. is not intended to be a complete summary of the rights and preferences of such securities and is subject to and qualified by reference to our amended and restated Certificate of Incorporation and our By-Laws by reference as e

Annual Report - FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) x Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2020. ? Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to . Commission File Number: 001-39597 MONTES ARCHIME

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ___)* Montes Archimedes Acquisition Corp. (Name of Issuer) Class A Common Stock (Title of Class of Securitie

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Montes Archimedes Acquisition Corp. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 612657106 (CUSIP Number) 18 February 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule purs

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 Montes Archimedes Acquisition Corp. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 Montes Archimedes Acquisition Corp. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 612657106 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) MONTES ARCHIMEDES ACQUISITION CORP. (Name of Issuer) CLASS A COMMON STOCK, PAR VALUE $0.0001 PER SHARE (T

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) MONTES ARCHIMEDES ACQUISITION CORP. (Name of Issuer) CLASS A COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 612657106 (CUSIP Number) DECEMBER 31, 2020 (Date of event which requires filing of this statement) Check the appropriate

Financial Statements and Exhibits, Other Events - FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 25, 2020 MONTES ARCHIMEDES ACQUISITION CORP. (Exact name of registrant as specified in its charter) Delaware 001-39597 85-1830874 (State or other jurisdiction of inco

Montes Archimedes Acquisition Corp. Announces the Separate Trading of its Shares of Class A Common Stock and Warrants Commencing November 27, 2020

Exhibit 99.1 Montes Archimedes Acquisition Corp. Announces the Separate Trading of its Shares of Class A Common Stock and Warrants Commencing November 27, 2020 November 25, 2020 — Montes Archimedes Acquisition Corp. (Nasdaq: MAACU) (the “Company”) announced that, commencing November 27, 2020, holders of the units sold in the Company’s initial public offering of 41,071,823 units, completed on Octob

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 ¨ TRANSITION REPORT PURSUANT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to MONTES ARCHIMEDES ACQUISITION CORP. (Exact name of

MONTES ARCHIMEDES ACQUISITION CORP. BALANCE SHEET

Exhibit 99.1 MONTES ARCHIMEDES ACQUISITION CORP. BALANCE SHEET October 9, 2020 Pro Forma Adjustments As Adjusted (Unaudited) (Unaudited) Assets: Current assets: Cash $ 1,737,630 $ 10,718,230 (a) $ 1,737,630 214,365 (b) (214,365 ) (c) (10,718,230 ) (g) Prepaid expenses 210,300 - 210,300 Due from underwriters 520,000 13,934 (e) 533,934 Total current assets 2,467,930 13,934 2,481,864 Cash held in Tru

Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2020 MONTES ARCHIMEDES ACQUISITION CORP. (Exact name of registrant as specified in its charter) Delaware 001-39597 85-1830874 (State or other jurisdiction of inco

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 MONTES ARCHIMEDES ACQUISITION CORP. (Name of Issuer) CLASS A COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 MONTES ARCHIMEDES ACQUISITION CORP. (Name of Issuer) CLASS A COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 612657205** (CUSIP Number) OCTOBER 7, 2020 (Date of event which requires filing of this statement) Check the appropriate box to designate t

MONTES ARCHIMEDES ACQUISITION CORP.

Exhibit 99.1 MONTES ARCHIMEDES ACQUISITION CORP. Report of Independent Registered Public Accounting Firm F-2 Balance Sheet as of October 9, 2020 F-3 Notes to Financial Statement F-4 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Shareholders and the Board of Directors of Montes Archimedes Acquisition Corp. Opinion on the Financial Statement We have audited the accompanying balance

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 9, 2020 MONTES ARCHIMEDES ACQUISITION CORP. (Exact name of registrant as specified in its charter) Delaware 001-39597 85-1830874 (State or other jurisdiction of incorp

Investment Management Trust Agreement between Continental Stock Transfer & Trust Company and Montes Archimedes Acquisition Corp. (incorporated herein by reference to Exhibit 10.1 of Montes Archimedes Acquisition Corp.’s Current Report on Form 8-K, filed with the SEC on October 13, 2020)

Exhibit 10.1 INVESTMENT MANAGEMENT TRUST AGREEMENT This Investment Management Trust Agreement (this “Agreement”) is made effective as of October 6, 2020 by and between Montes Archimedes Acquisition Corp., a Delaware corporation (the “Company”), and Continental Stock Transfer & Trust Company, a New York corporation (the “Trustee”). WHEREAS, the Company’s registration statement on Form S-1, No. 333-

Administrative Services Agreement between the Company and an affiliate of the Sponsor

Exhibit 10.5 MONTES ARCHIMEDES ACQUISITION CORP. 724 Oak Grove, Suite 130 Menlo Park, CA 94025 October 6, 2020 Patient Square Capital LP 724 Oak Grove, Suite 130 Menlo Park, CA 94025 Re: Administrative Support Agreement Ladies and Gentlemen: This letter agreement by and between Montes Archimedes Acquisition Corp. (the “Company”) and Patient Square Capital LP (“PSC”), dated as of the date hereof, w

Registration and Stockholder Rights Agreement among the Company, the Sponsor and certain directors of the company(1)

Exhibit 10.2 REGISTRATION AND STOCKHOLDER RIGHTS AGREEMENT THIS REGISTRATION AND STOCKHOLDERS RIGHTS AGREEMENT (this “Agreement”) is entered into as of October 6, 2020, by Montes Archimedes Acquisition Corp., a Delaware corporation (the “Company”), Patient Square Capital LLC, a Delaware limited liability company (the “Sponsor”), and the additional undersigned parties listed under Holder on the sig

Letter Agreement between the Company and each director and executive officer of the Company(1)

Exhibit 10.9 October 6, 2020 Montes Archimedes Acquisition Corp. 724 Oak Grove, Suite 130 Menlo Park, CA 94025 Re: Initial Public Offering Ladies and Gentlemen: This letter (the “Letter Agreement”) is being delivered to you in accordance with the Underwriting Agreement (the “Underwriting Agreement”) entered into by and between Montes Archimedes Acquisition Corp., a Delaware corporation (the “Compa

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits - FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 13, 2020 (October 6, 2020) MONTES ARCHIMEDES ACQUISITION CORP. (Exact name of registrant as specified in its charter) Delaware 001-39597 85-1830874 (State or other jur

Warrant Agreement between Continental Stock Transfer & Trust Company and Montes Archimedes Acquisition Corp. (incorporated herein by reference to Exhibit 4.1 of Montes Archimedes Acquisition Corp.’s Current Report on Form 8-K, filed with the SEC on October 13, 2020)

Exhibit 4.1 WARRANT AGREEMENT between MONTES ARCHIMEDES ACQUISITION CORP. and CONTINENTAL STOCK TRANSFER & TRUST COMPANY Dated October 6, 2020 THIS WARRANT AGREEMENT (this “Agreement”), dated as of October 6, 2020, is by and between Montes Archimedes Acquisition Corp., a Delaware corporation (the “Company”), and Continental Stock Transfer & Trust Company, a New York corporation, as warrant agent (

Private Placement Warrants Purchase Agreement between the Company and the Sponsor(1)

Exhibit 10.3 PRIVATE PLACEMENT WARRANTS PURCHASE AGREEMENT THIS PRIVATE PLACEMENT WARRANTS PURCHASE AGREEMENT, dated as of October 6, 2020 (as it may from time to time be amended and including all exhibits referenced herein, this “Agreement”), is entered into by and between Montes Archimedes Acquisition Corp., a Delaware corporation (the “Company”), and Patient Square Capital LLC, a Delaware limit

Letter Agreement between the Company and the Sponsor(1)

Exhibit 10.8 October 6, 2020 Montes Archimedes Acquisition Corp. 724 Oak Grove, Suite 130 Menlo Park, CA 94025 Re: Initial Public Offering Ladies and Gentlemen: This letter (the “Letter Agreement”) is being delivered to you in accordance with the Underwriting Agreement (the “Underwriting Agreement”) entered into by and between Montes Archimedes Acquisition Corp., a Delaware corporation (the “Compa

Amended and Restated Certificate of Incorporation (1)

Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF MONTES ARCHIMEDES ACQUISITION CORP. October 6, 2020 Montes Archimedes Acquisition Corp., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), DOES HEREBY CERTIFY AS FOLLOWS: 1. The name of the Corporation is Montes Archimedes Acquisition Corp.. The original certificate of incorporation of

Underwriting Agreement by and between the Company, Citigroup Global Markets Inc. and Jefferies LLC

Exhibit 1.1 Montes Archimedes Acquisition Corp. 40,000,000 Units UNDERWRITING AGREEMENT New York, New York October 6, 2020 Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10013 Jefferies LLC 520 Madison Avenue New York, New York 10022 As Representatives of the several underwriters listed in Schedule I hereto (the “Underwriters”) Ladies and Gentlemen: Montes Archimedes Acquisi

Montes Archimedes Acquisition Corp. 40,000,000 Units

Use these links to rapidly review the document TABLE OF CONTENTS INDEX TO FINANCIAL STATEMENTS Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No.

-

begin 644 8ACertMAAC.pdf M)5!$1BTQ+C4-)>+CS],-"C@Q(# @;V)J#3P\+TQI;F5A7!E+UA2968O5ULQ(#(@,5T^/G-T7!E+U!A M9V4^/@UE;F1O8FH-.#0@,"!O8FH-/#PO1FEL=&5R+T9L871E1&5C;V1E+T9I M<&4O3V)J4W1M/CYS=')E86T- M"FC>[!A=;]LV\*P<4.1\4O\ HH CE=W 9:TF[-V0) 'U=$288XON63TSG[HURN*WYRQL]7[5VY MY-,)DS\(N%CI'SX>,8DGT]8UWZM^/RL7/\)K$W%+Q[O*[NH7L[\JNXHN2 MY%;WO=SQ,>I?+ZJFPT MGY;W/U7US6W'G+3\QZHG'6GA^&Q9WJR95GRV:KJ3 MD]7#Y9'TB

- 8-A12B

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 MONTES ARCHIMEDES ACQUISITION CORP.

MONTES ARCHIMEDES ACQUISITION CORP A Delaware corporation (Adopted as of July 6, 2020) ARTICLE I

Exhibit 3.3 Execution Version BY-LAWS OF MONTES ARCHIMEDES ACQUISITION CORP A Delaware corporation (Adopted as of July 6, 2020) ARTICLE I OFFICES Section 1. Registered Office. The registered office of the corporation in the State of Delaware is located at 1209 Orange Street, in the City of Wilmington, County of New Castle, 19801. The name of its registered agent at such address is The Corporation

Certificate of Incorporation.

Exhibit 3.1 CERTIFICATE OF INCORPORATION OF MONTES ARCHIMEDES ACQUISITION CORP ARTICLE ONE The name of the corporation is Montes Archimedes Acquisition Corp (hereinafter called the “Corporation”). ARTICLE TWO The address of the Corporation’s registered office in the State of Delaware is 1209 Orange Street, in the City of Wilmington, County of New Castle, 19801. The name of its registered agent at

- S-1/A

Use these links to rapidly review the document TABLE OF CONTENTS INDEX TO FINANCIAL STATEMENTS Table of Contents Filed with the U.

Form of Indemnity Agreement(3)

Exhibit 10.4 INDEMNITY AGREEMENT THIS INDEMNITY AGREEMENT (this “Agreement”) is made as of , 2020, by and between Montes Archimedes Acquisition Corp., a Delaware corporation (the “Company”), and [·] (the “Indemnitee”). RECITALS WHEREAS, highly competent persons have become more reluctant to serve publicly-held corporations as directors, officers or in other capacities unless they are provided with

Form of Amended and Restated Certificate of Incorporation.

EXHIBIT 3.2 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF MONTES ARCHIMEDES ACQUISITION CORP. September [ ], 2020 Montes Archimedes Acquisition Corp., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), DOES HEREBY CERTIFY AS FOLLOWS: 1. The name of the Corporation is Montes Archimedes Acquisition Corp.. The original certificate of incorporation

Form of Warrant Agreement between Continental Stock Transfer & Trust Company and the Registrant.

EX-4.4 7 a2242417zex-44.htm EX-4.4 Exhibit 4.4 WARRANT AGREEMENT between MONTES ARCHIMEDES ACQUISITION CORP. and CONTINENTAL STOCK TRANSFER & TRUST COMPANY Dated , 2020 THIS WARRANT AGREEMENT (this “Agreement”), dated as of , 2020, is by and between Montes Archimedes Acquisition Corp., a Delaware corporation (the “Company”), and Continental Stock Transfer & Trust Company, a New York corporation, a

Administrative Services Agreement between the Company and an affiliate of the Sponsor (1)

Exhibit 10.5 MONTES ARCHIMEDES ACQUISITION CORP. 724 Oak Grove, Suite 130 Menlo Park, CA 94025 , 2020 Patient Square Capital LLC 724 Oak Grove, Suite 130 Menlo Park, CA 94025 Re: Administrative Support Agreement Ladies and Gentlemen: This letter agreement by and between Montes Archimedes Acquisition Corp. (the “Company”) and Patient Square Capital LLC (“Sponsor”), dated as of the date hereof, will

Specimen Class A Common Stock Certificate of Montes Archimedes Acquisition Corp. (incorporated herein by reference to Exhibit 4.2 of Montes Archimedes Acquisition Corp.’s Amendment No. 1 to the Registration Statement on Form S-1, filed with the SEC on September 24, 2020)

Exhibit 4.2 NUMBER C- SHARES SPECIMEN CLASS A COMMON STOCK CERTIFICATE SEE REVERSE FOR CERTAIN DEFINITIONS CUSIP [·] MONTES ARCHIMEDES ACQUISITION CORP. INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE CLASS A COMMON STOCK This Certifies that is the owner of FULLY PAID AND NON-ASSESSABLE SHARES OF THE PAR VALUE OF $0.0001 EACH OF THE CLASS A COMMON STOCK OF MONTES ARCHIMEDES ACQUISITION CORP.

Promissory Note, dated July 23, 2020, issued to the Sponsor.(3)

EXHIBIT 10.6 THIS PROMISSORY NOTE (“NOTE”) HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COMPANY

Securities Subscription Agreement, dated July 23, 2020, between the Registrant and the Sponsor.

EXHIBIT 10.7 MONTES ARCHIMEDES ACQUISITION CORP. 724 Oak Grove, Suite 130 Menlo Park, CA 94025 July 23, 2020 Patient Square Capital LP 8240 McDaniel Road Fort Worth, TX 76126 RE: Securities Subscription Agreement Ladies and Gentlemen: We are pleased to accept the offer Patient Square Capital LP (the “Subscriber” or “you”) has made to purchase 14,375,000 shares of Class B common stock (the “Shares”

Form of Investment Management Trust Agreement between Continental Stock Transfer & Trust Company and the Registrant.

Exhibit 10.1 INVESTMENT MANAGEMENT TRUST AGREEMENT This Investment Management Trust Agreement (this “Agreement”) is made effective as of September , 2020 by and between Montes Archimedes Acquisition Corp., a Delaware corporation (the “Company”), and Continental Stock Transfer & Trust Company, a New York corporation (the “Trustee”). WHEREAS, the Company’s registration statement on Form S-1, No. 333

Power of Attorney (included on signature page).*

Use these links to rapidly review the document TABLE OF CONTENTS INDEX TO FINANCIAL STATEMENTS Table of Contents Filed with the U.

Consent of George Barrett.

Exhibit 99.1 CONSENT OF GEORGE BARRETT Montes Archimedes Acquisition Corp. (the “Company”) intends to file a Registration Statement on Form S-1 (together with any amendments or supplements thereto, the “Registration Statement”) registering securities for issuance in its initial public offering. As required by Rule 438 under the Securities Act of 1933, as amended, the undersigned hereby consents to

Form of Private Placement Warrants Purchase Agreement between the Registrant and the Sponsor.

Exhibit 10.3 PRIVATE PLACEMENT WARRANTS PURCHASE AGREEMENT THIS PRIVATE PLACEMENT WARRANTS PURCHASE AGREEMENT, dated as of , 2020 (as it may from time to time be amended and including all exhibits referenced herein, this “Agreement”), is entered into by and between Montes Archimedes Acquisition Corp., a Delaware corporation (the “Company”), and Patient Square Capital LLC, a Delaware limited liabil

Specimen Unit Certificate of Montes Archimedes Acquisition Corp. (incorporated herein by reference to Exhibit 4.1 of Montes Archimedes Acquisition Corp.’s Amendment No. 1 to the Registration Statement on Form S-1, filed with the SEC on September 24, 2020)

Exhibit 4.1 NUMBER UNITS U- SEE REVERSE FOR CERTAIN DEFINITIONS CUSIP [ ] MONTES ARCHIMEDES ACQUISITION CORP. UNITS CONSISTING OF ONE SHARE OF CLASS A COMMON STOCK AND ONE-HALF OF ONE WARRANT TO PURCHASE ONE SHARE OF CLASS A COMMON STOCK THIS CERTIFIES THAT is the owner of Units. Each Unit (“Unit”) consists of one (1) share of Class A common stock, par value $0.0001 per share (“Common Stock”), of

Form of Letter Agreement among the Registrant and each director and executive officer of the Registrant.

Exhibit 10.9 , 2020 Montes Archimedes Acquisition Corp. 724 Oak Grove, Suite 130 Menlo Park, CA 94025 Re: Initial Public Offering Ladies and Gentlemen: This letter (the “Letter Agreement”) is being delivered to you in accordance with the Underwriting Agreement (the “Underwriting Agreement”) entered into by and between Montes Archimedes Acquisition Corp., a Delaware corporation (the “Company”) and

Consent of Stephen Oesterle.*

Exhibit 99.2 CONSENT OF STEVE OESTERLE Montes Archimedes Acquisition Corp. (the “Company”) intends to file a Registration Statement on Form S-1 (together with any amendments or supplements thereto, the “Registration Statement”) registering securities for issuance in its initial public offering. As required by Rule 438 under the Securities Act of 1933, as amended, the undersigned hereby consents to

Form of Registration and Stockholder Rights Agreement among the Registrant, the Sponsor and the Holders signatory thereto.

Exhibit 10.2 REGISTRATION AND STOCKHOLDER RIGHTS AGREEMENT THIS REGISTRATION AND STOCKHOLDERS RIGHTS AGREEMENT (this “Agreement”) is entered into as of , 2020, by Montes Archimedes Acquisition Corp., a Delaware corporation (the “Company”), Patient Square Capital LLC, a Delaware limited liability company (the “Sponsor”), and the additional undersigned parties listed under Holder on the signature pa

Form of Underwriting Agreement.

Exhibit 1.1 Montes Archimedes Acquisition Corp. 50,000,000 Units UNDERWRITING AGREEMENT New York, New York September [·], 2020 Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10013 Jefferies LLC 520 Madison Avenue New York, New York 10022 As Representatives of the several underwriters listed in Schedule I hereto (the “Underwriters”) Ladies and Gentlemen: Montes Archimedes Acq

Form of Letter Agreement between the Registrant and the Sponsor.

Exhibit 10.8 , 2020 Montes Archimedes Acquisition Corp. 724 Oak Grove, Suite 130 Menlo Park, CA 94025 Re: Initial Public Offering Ladies and Gentlemen: This letter (the “Letter Agreement”) is being delivered to you in accordance with the Underwriting Agreement (the “Underwriting Agreement”) entered into by and between Montes Archimedes Acquisition Corp., a Delaware corporation (the “Company”) and

Specimen Warrant Certificate of Montes Archimedes Acquisition Corp. (incorporated herein by reference to Exhibit 4.3 of Montes Archimedes Acquisition Corp.’s Amendment No. 1 to the Registration Statement on Form S-1, filed with the SEC on September 24, 2020)

Exhibit 4.3 [Form of Warrant Certificate] [FACE] Number Warrants THIS WARRANT SHALL BE VOID IF NOT EXERCISED PRIOR TO THE EXPIRATION OF THE EXERCISE PERIOD PROVIDED FOR IN THE WARRANT AGREEMENT DESCRIBED BELOW MONTES ARCHIMEDES ACQUISITION CORP. Incorporated Under the Laws of the State of Delaware CUSIP [·] Warrant Certificate This Warrant Certificate certifies that , or registered assigns, is the

Registration Statement - S-1

Use these links to rapidly review the document TABLE OF CONTENTS INDEX TO FINANCIAL STATEMENTS Table of Contents Filed with the U.

-

Use these links to rapidly review the document TABLE OF CONTENTS INDEX TO FINANCIAL STATEMENTS Table of Contents This is a confidential draft submission to the U.